ALM Properties, Inc.
Page printed from: Corporate Counsel
Select 'Print' in your browser menu to print this document.
FTC Vows Strong Action After Pay-for-Delay Ruling
The Federal Trade Commission is planning strong court attacks against so-called "pay-for-delay" generic drug settlements in response to a U.S. Supreme Court ruling in June, commission Chairwoman Edith Ramirez told a Senate committee Tuesday on Capitol Hill.
The high court's ruling in FTC v. Actavis, Inc. left the agency in a much stronger position to combat settlements that regulators see as anticompetitive, starting with the continued investigation and litigation of two active cases, Ramirez told the Subcommittee on Antitrust, Competition Policy and Consumer Rights.
But Ramirez also urged the Senate to pass now-proposed bipartisan legislation that would put the burden in these cases on the drug companies to prove their settlements are not anticompetitive. Litigation is costly and time-consuming for the agency, she said.
That legislation, proposed by Senator Amy Klobuchar (D-Minn.) and co-sponsored by Senator Chuck Grassley (R-Iowa), would make drug company pay-for-delay settlements presumptively illegal, instead of the typical "rule of reason" antitrust test now in place after the Supreme Court ruling. Much of the hearing was spent debating which standard is better for consumers.
“While the rule of reason standard is an appropriate test and we intend to apply that going forward, I do believe declaring them presumptively invalid would also further help us put a stop to these types of settlements,” Ramirez said.
The two cases that the FTC is litigating are Actavis, as well as FTC v. Cephalon case in the U.S. District Court for the Eastern District of Pennsylvania.
Michael Carrier, a professor at Rutgers University School of Law in New Jersey, testified today that the legislation would be good for consumers and send a clear message to courts on these types of patent settlements.
"Antitrust alarm bells should be going off when one company is paying another company to stay out of the market," Carrier said.
Arnold & Porter partner Diane Bieri testified at the hearing on behalf of pharmaceutical research and manufacturing companies, telling the subcommittee that the parties often prefer to minimize costs, minimize litigation risks and deal with uncertainty by settling these cases rather than litigating them.
This story originally appeared as a post on The BLT: The Blog of Legal Times.